ViiV's Dovato Could Challenge Status Quo In Naive EU HIV Patients

 
• By John Davis

The approval of ViiV’s new once-daily, two-drug single-pill for HIV/AIDS could lead to a tough battle in Europe with established therapies.   

Mountain
Reaching the top spot in HIV/AIDS therapies will likely be a tough climb. • Source: Shutterstock

More from New Products

More from Scrip